A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension

E
Elizabeth Martin

Primary Investigator

Overview

Glaucoma treatment study

Description

This study is evaluating the duration and safety of a topical medication (Bimatoprost SR) for people who have OAG or OHT.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    eye,eyes,vision,glaucoma,open-angle glaucoma,ocular hypertension,OAG,POAG,OHT,1904606314
  • Age: Between 18 Years - 100 Years
  • Gender: All

Eligibility Criteria
Diagnosis of either OAG (ie, primary OAG, pseudoexfoliation glaucoma,
pigmentary glaucoma) or OHT in the study eye, requiring IOP-lowering treatment
 
Exclusion Criteria
Previous glaucoma eye surgery
Additional Information:

Updated on 23 Aug 2023. Study ID: 1904606314

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center